SCHEMBL6884541

SCHEMBL6884541

CC(C)CS(=O)(=O)N[C@@H](Cn1cnc2c(N3CCC(C(=O)O)CC3)ncnc21)C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 5/20 0.33
KDM4E B2RXH2 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
MEN1 O00255 2/20 0.33
SIRT2 Q8IXJ6 2/20 0.33
SIRT1 Q96EB6 2/20 0.33
SIRT3 Q9NTG7 2/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
ALDH1A1 P00352 4/20 0.33
HRH4 Q9H3N8 1/20 0.33
HTR2C P28335 1/20 0.32
CACNA1B Q00975 1/20 0.32
HSD17B10 Q99714 2/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27475141 1.00 KMT2A (0.34) KMT2APOLBMAPTKDM4ESMN1; SMN2
SCHEMBL6876016 0.85 MMP13 (0.40) KMT2APOLBMAPTKDM4ESMN1; SMN2
SCHEMBL27475140 0.85 MMP13 (0.40) KMT2APOLBMAPTKDM4ESMN1; SMN2
SCHEMBL6879623 0.84 MAPT (0.34) KMT2AMAPTMEN1SIRT2SIRT1
SCHEMBL6884268 0.84 MAPT (0.35) KMT2APOLBMAPTKDM4ESMN1; SMN2
SCHEMBL27551534 0.83 SIRT2 (0.32) KMT2APOLBMAPTKDM4ESMN1; SMN2
SCHEMBL4640097 0.82 TDP1 (0.36) KMT2APOLBMAPTKDM4ESMN1; SMN2
SCHEMBL27474218 0.81 KMT2A (0.39) KMT2APOLBMAPTKDM4ESMN1; SMN2
SCHEMBL4640715 0.81 KMT2A (0.39) KMT2APOLBMAPTKDM4ESMN1; SMN2
SCHEMBL27524220 0.79 ITGB3 (0.46) CNR1CNR2HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1171888-C Substituted purine derivatives, preparation method and application ���ĵ�˹ҩƷ�¹��ɷ����޹�˾ 2004-10-20 CN disclosed
US-6747016-B1 TREATING OSTEOPOROSIS IN WARM-BLOODED ANIMALS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-06-08 US disclosed
EP-1196416-B1 SUBSTITUTED PURINE DERIVATIVES AS INHIBITORS OF CELL ADHESION AVENTIS PHARMA GMBH (DE) 2004-03-24 EP disclosed
CN-1371376-A substituted purine derivatives as cell adhesion inhibitors AVENTIS PHARMA GMBH (DE) 2002-09-25 CN disclosed
EP-1196416-A1 SUBSTITUTED PURINE DERIVATIVES AS INHIBITORS OF CELL ADHESION Aventis Pharma Deutschland GmbH (DE) 2002-04-17 EP disclosed
WO-2001002399-A1 SUBSTITUTED PURINE DERIVATIVES AS INHIBITORS OF CELL ADHESION AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-01-11 WO disclosed
EP-1065208-A1 Substituted purine derivatives as inhibitors of cell adhesion Aventis Pharma Deutschland GmbH (DE) 2001-01-03 EP disclosed